Will 2 February target for Ampligen US verdict be a 'Groundhog Day' scenario?
This article was originally published in Scrip
Pennsylvania biotech Hemispherx Biopharma is likely keeping its fingers crossed the 2 February "Groundhog Day" action date set by the US FDA for its verdict on Ampligen, an experimental chronic fatigue syndrome (CFS) therapy, does not take the same path as the iconic Bill Murray weatherman character in the 1993 film – trusting the current review will be the last for the application, without another repeat in store.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.